Tag: Cancer: Skin
Anti-CTAg Antibodies Identified in Stage I, II Melanoma
Specific antibodies against three tumor antigens identified as promising diagnostic biomarkers for early-stage melanomas
Melanoma Incidence, Mortality Declining in Those Aged 30 to 49 Years
Melanoma incidence decreased for those aged 20 to 29, 30 to 39, 40 to 49 years; decline in melanoma mortality seen for those aged 30 to 59 years
Prevalence of Skin Cancer Varies for Sexual Minority, Heterosexual Adults
Hispanic and non-Hispanic Black sexual minority males and females have higher rates of skin cancer than their heterosexual counterparts
Rural Residents Continue to Have Higher Odds of Skin Cancer
Rural-urban differences magnified by lower income and race
Few Patients With Positive Margins After Basal Cell Excision Have Recurrence
Recurrence developed in more patients who did not receive additional treatment and in fewer receiving nonsurgical treatments
Nonsignificant Survival Benefit Seen for Dabrafenib, Trametinib in Melanoma
Consistent survival benefit seen across several prespecified subgroups, including those with a BRAF V600E mutation
ASCO: Neoadjuvant Ipilimumab + Nivolumab Ups Survival in Resectable Melanoma
Neoadjuvant treatment followed by surgery results in longer event-free survival for resectable, macroscopic stage III melanoma
Non-Hispanic Black Melanoma Patients Present With Advanced Disease
T category and stage at presentation higher for non-Hispanic Black patients
Second Primary Malignancy Risk Increased After Cutaneous B-Cell Lymphoma
Women have increased risk for thyroid, renal, lung cancers; men have highest risk for melanoma, bladder, prostate cancers
AAD: Concerns Noted Relating to Use of AI Dermatology Apps
None of the apps are approved by the FDA; only two include disclaimers for lack of regulatory approval
